| Literature DB >> 19320988 |
Björn Ställberg1, Mika Nokela, Per-Olof Ehrs, Paul Hjemdal, Eva Wikström Jonsson.
Abstract
BACKGROUND: Patient centred outcomes, such as health status, are important in Chronic Obstructive Pulmonary Disease (COPD). Extensive questionnaires on health status have good measurement properties, but are not suitable for use in primary care. The newly developed, short Clinical COPD Questionnaire, CCQ, was therefore validated against the St George's Respiratory Questionnaire (SGRQ).Entities:
Mesh:
Year: 2009 PMID: 19320988 PMCID: PMC2666647 DOI: 10.1186/1477-7525-7-26
Source DB: PubMed Journal: Health Qual Life Outcomes ISSN: 1477-7525 Impact factor: 3.186
Baseline characteristics for the entire study sample with clinical COPD and the subgroup with verified COPD
| Subjects | 111 | 83 |
| Female (%) | 65.8 | 62.7 |
| Age years, mean, (range) | 67.1, (42–85) | 67.1, (42–85) |
| Smoking habits (%) | ||
| Non-smokers | 2.8 | 1.2 |
| Ex-smokers | 56.9 | 61.4 |
| Smokers | 40.4 | 34.9 |
| Missing data | 1.8 | 2.4 |
| Disease known since, (%) | ||
| < 1 yrs | 19.8 | 10.8 |
| 1–5 yrs | 37.8 | 39.8 |
| > 5 yrs | 42.3 | 49.4 |
| BMI, mean, (range) | 24.4, (17–39) | 24.2, (17–39) |
| FEV1/FVC ratio – mean (SD), range | 57.8 (14.3), range (26.0–92.6) | 52.4 (11.4), range (26.0–69.0) |
| FEV1, % predicted, mean (SD), range | 58.1 (20.2), range (14.8–111.5) | 52.5 (17.9), range (14.8–102.6) |
| Severity classification, (%) FEV1 (post bronch. dil.) | ||
| FEV1 ≥ 80% predicted | 11.0 | 7.3 |
| 50% ≤ FEV1 < 80% predicted | 52.3 | 46.3 |
| 30% ≤ FEV1 < 50% predicted | 30.3 | 37.8 |
| FEV1 < 30% predicted | 6.4 | 8.5 |
| Medication visit 1 (visit 2)# | ||
| - Only SABA or ipratropium as needed (%) | 4.5 (6.5) | 6.1 (6.3) |
| - Ipratropium, tiotropium, LABA or SABA as regular medication (%) | 28.2 (26.2) | 26.8 (26.6) |
| - Ipratropium, tiotropium, LABA or SABA | 50.0 (50.5 | 54.9 (55.7) |
| - ICS without any regular brochodilators (%) | 3.6 (6.5) | 2.4 (5.1) |
| - No medication (%) | 13.6 (10.3) | 9.8 (6.3) |
| - Missing data (n) | 1 (4) | 1 (4) |
*Including four patients with missing data for the ratio FEV1/FVC. ** At visit 1.
#Medication during the week preceding the two visits.
BMI = body mass index, FEV1 = forced expiratory volume in one second, SABA= short-acting beta 2-agonist, LABA = long-acting beta 2-agonist, ICS = inhaled corticosteroids.
Figure 1Baseline SF-36 domain scores for the entire study sample, (n = 111, unfilled squares), COPD verified by spirometry (n = 83, filled triangles). National norm data (filled circles) for reference. pf = physical functioning, rp = role-physical, bp = bodily pain, gh = general health, vt = vitality, sf = social functioning, re = role-emotional, mh = mental health.
Baseline mean values in each of the instruments for the entire study sample
| Domain | SGRQ | CCQ | Correlation | SGRQ | CCQ |
| Total** | 40.91 ± 17.89 | 2.33 ± 1.03 | 0.84 | 0.90 | 0.84 |
| Symptoms** | 47.91 ± 21.92 | 2.57 ± 1.17 | 0.70 | 0.75 | 0.67 |
| Functional State#/Activity* | 54.68 ± 23.84 | 2.03 ± 1.22 | 0.74 | 0.84 | 0.86 |
| Mental State# | 2.44 ± 1.75 | 0.82 | |||
| Impacts* | 30.93 ± 18.16 | 0.82 |
** Domain shared by both instruments. * Domain in SGRQ only. # Domain in CCQ only. SGRQ alpha calculated on weighted items. SGRQ = St Georges Respiratory Questionnaire, CCQ = Clinical COPD Questionnaire.
Figure 2Relationship between SGRQ scores and other estimations for COPD in the entire study sample (n = 111). The group with COPD verified by spirometry (filled triangles), GP diagnosis of COPD not verified by spirometry (empty triangles). a. Scatterplot of SGRQ scores against CCQ scores. Intercept for the regression lines: 0.35: slope 0.048: r2 0.70. b. Change in SGRQ score between visit one and two plotted against change in CCQ score. Intercept for the regression lines: -0.22: slope 0.045: r2 0.32. c. Change in SGRQ scores plotted against GPs estimation of change between visit one and two displays large disagreement between the change in health status as recorded by the patient's SGRQ and the caregiver's estimation of change. The lines represent the minimal important difference (± 4) for SGRQ.
Reliability of the SGRQ and the CCQ
| ICC# | ICC* | |
| SGRQ | ||
| Total | 0.92 | 0.92 |
| Symptoms | 0.80 | 0.81 |
| Activity | 0.84 | 0.84 |
| Impacts | 0.85 | 0.85 |
| CCQ | ||
| Total | 0.85 | 0.85 |
| Symptoms | 0.74 | 0.75 |
| Functional state | 0.86 | 0.85 |
| Mental state | 0.83 | 0.83 |
#Reliability of instruments evaluated on the stable subgroup in the entire study sample with clinical COPD. *Reliability of instruments evaluated on the stable subgroup in the group with verified COPD. ICC (intra class correlation) calculated with a two-way mixed model of consistency. SGRQ = St Georges Respiratory Questionnaire, CCQ = Clinical COPD Questionnaire.
Cross sectional validity (n = 111)
| Total | Symptoms | Activity | Impacts | |
| Total | 0.88 | 0.77 | 0.79 | 0.82 |
| Symptoms | 0.77 | 0.80 | 0.63 | 0.70 |
| Functional state | 0.82 | 0.62 | 0.84 | 0.73 |
| Mental state | 0.64 | 0.55 | 0.50 | 0.63 |
All correlations significant at the 0.05 level (2-tailed) if not otherwise stated. Summary of sum score correlation coefficents calculated between all domains in both instruments. Calculations based on data from the second visit.
Longitudinal Validity (n = 111)
| Symptoms | Impacts | Activity | ||
| Total | 0.52 | 0.40 | 0.38 | 0.31 |
| Symptoms | 0.46 | 0.36 | 0.36 | 0.26 |
| Functional | ||||
| State | 0.44 | 0.27 | 0.31 | 0.33 |
| Mental State | 0.30 | 0.17 n.s | 0.18 n.s | 0.22 |
All correlations are significant at the 0.05 level (2-tailed) if not otherwise stated. Summary of change score correlation coefficients calculated between all domains in both instruments. Calculations based on data from both visits from the entire study sample with clinical COPD. SGRQ = St Georges Respiratory Questionnaire, CCQ = Clinical COPD Questionnaire.